Literature DB >> 19154466

The effect of sildenafil citrate on bladder outlet obstruction: a mouse model.

Charles R Beamon1, Carla Mazar, Mohamad W Salkini, Hardeep S Phull, Craig V Comiter.   

Abstract

OBJECTIVE: To investigate if sildenafil citrate can inhibit the functional and structural changes of the detrusor in a murine model of bladder outlet obstruction (BOO). Phosphodiesterase type 5 (PDE-5) inhibitors have recently been used for treating urinary symptoms associated with prostatic obstruction, but it is unclear whether PDE-5 inhibition acts on the prostatic urethra or the bladder.
MATERIALS AND METHODS: In 18 male Balb/CAN mice, partial BOO was created and the mice allowed to survive for 6 weeks. Half of the mice (nine) were treated with oral sildenafil citrate daily (10 mg/kg) by oral lavage (BOO + V), and half (nine) were not (BOO). Six mice were used as sham-operated controls and received no sildenafil. The mice were assessed by urodynamics at baseline and after 6 weeks, with a measurement of volume at first uninhibited non-voiding contraction (V(DO1)), bladder capacity (BC), and detrusor pressure during void (Pdet). At 6 weeks, bladders were harvested, fixed and sectioned, and stained with haematoxylin and eosin (H&E) and trichrome stain. Detrusor muscle hypertrophy and fibrosis were evaluated on a scale of 1 (decreased) to 3 (increased), by two urologists and one pathologist unaware of the treatment group; the results were compared with those from normal controls.
RESULTS: BOO mice had a significantly greater BC than control mice, with a mean (SD) of 153 (66) vs 58 (13) microL (P = 0.004). Treatment with sildenafil did not significantly alter BC. BOO caused an increase in Pdet compared to controls, with a mean (SD) of 25 (7) vs 12 (5) cm H2O. P(det) was not significantly different after treatment with sildenafil. The median V(DO1) as a percentage of BC was significantly lower in BOO than in control mice (20% vs 53%, P > 0.03) and increased significantly after sildenafil treatment (20% vs 44%, P = 0.04). BOO was associated with a greater bladder weight than in control mice, with a mean (SD) of 89 (32) vs 27 (6) mg (P = 0.001), which was decreased with sildenafil treatment, to 40 (14) vs 89 (32) mg (P = 0.013). BOO caused an increase in detrusor muscular hypertrophy vs control mice, with a median H&E score of 3 vs 2 (P = 0.01) and an increase in fibrosis vs control mice, with a median trichrome score of 3 vs 2 (P = 0.01). BOO + V mice had reduced muscular hypertrophy and fibrosis, with a median H&E score of 3 vs 2 (P = 0.01) and a median trichrome score of 3 vs 1 (P = 0.01).
CONCLUSIONS: BOO mediates both functional and structural changes in the mouse bladder. Six weeks of obstruction caused an increase in BC, detrusor overactivity and voiding pressure, and mediated an increase in bladder weight, detrusor muscle hypertrophy and collagen deposition in the lamina propria and smooth muscle. Treatment with 6 weeks of oral sildenafil beginning at the time of BOO prevented the increase in detrusor overactivity without affecting voiding pressures, and prevented the increase in detrusor muscle hypertrophy and collagen deposition that otherwise occurred with BOO. It appears therefore that sildenafil citrate acts on the bladder rather than on the outlet.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19154466     DOI: 10.1111/j.1464-410X.2008.08324.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  13 in total

1.  Impact of partial urethral obstruction on bladder function: time-dependent changes and functional correlates of altered expression of Ca²⁺ signaling regulators.

Authors:  David Burmeister; Tamer AbouShwareb; Ralph D'Agostino; Karl-Erik Andersson; George J Christ
Journal:  Am J Physiol Renal Physiol       Date:  2012-03-21

Review 2.  Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.

Authors:  Stefan Uckert; Matthias Oelke
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

Review 3.  Research Findings on Overactive Bladder.

Authors:  Phani B Patra; Sayani Patra
Journal:  Curr Urol       Date:  2015-05-20

4.  Benign prostatic hyperplasia/obstruction ameliorated using a soluble guanylate cyclase activator.

Authors:  Irina V Zabbarova; Youko Ikeda; Mark G Kozlowski; Pradeep Tyagi; Lori A Birder; Basu Chakrabarty; Subashan Kpg Perera; Rajiv Dhir; Adam C Straub; Peter Sandner; Karl-Erik Andersson; Marcus J Drake; Christopher H Fry; Anthony J Kanai
Journal:  J Pathol       Date:  2022-02-15       Impact factor: 9.883

5.  Nerve-sparing Mid-urethral Obstruction (NeMO) in Female Small Rodents.

Authors:  Martin Sidler; Karen J Aitken; Jia Xin Jiang; Darius J Bägli
Journal:  J Vis Exp       Date:  2017-04-25       Impact factor: 1.355

Review 6.  The role of phosphodiesterases in bladder pathophysiology.

Authors:  Mohammad S Rahnama'i; Stefan Ückert; Ramona Hohnen; Gommert A van Koeveringe
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

Review 7.  The role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.

Authors:  Mehmet Umul; Tekin Ahmet Serel
Journal:  Turk J Urol       Date:  2013-12

8.  Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Hartmut Porst; Peter Sandner; Ernst Ulbrich
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

Review 9.  Muro-Neuro-Urodynamics; a Review of the Functional Assessment of Mouse Lower Urinary Tract Function.

Authors:  Hiroki Ito; Anthony E Pickering; Yasuhiko Igawa; Anthony J Kanai; Christopher H Fry; Marcus J Drake
Journal:  Front Physiol       Date:  2017-02-06       Impact factor: 4.566

10.  Influence of sildenafil on blood oxygen saturation of the obstructed bladder.

Authors:  Jeroen R Scheepe; Arjen Amelink; Katja P Wolffenbuttel; Dirk J Kok
Journal:  BMC Urol       Date:  2014-05-29       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.